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Continuous bioprocessing offers numerous benefits that have been highlighted recently in the literature. 
While substantial research efforts have allowed for relevant developments in continuous cell culture 
processes, downstream challenges, such as continuous viral inactivation, have not been addressed. The 
purpose of this work is to design a chamber that incubates a continuous product stream for a desired 
incubation time, typically for 1 hour.  Since plug-flow cannot be achieved at typical incubation times and 
flow rates, one of the biggest challenges is to address dispersion of the product stream. Since several 
logs of viral clearance should be achieved during a virus removal step, the restriction is that only 1-10ppm 
of the original product should exit the chamber before the specified time. In this work, an initial design is 
chosen such that the incubation chamber is easy to handle, has a small footprint, and there are no 
pressure concerns at the desired flow rates. Pulse response experiments have been performed to 
generate cumulative residence time distribution functions. The average residence time distribution 
function was used to find the time at which 1 ppm of the original tracer concentration passes through the 
chamber. An orthogonal method should be used to verify that the diluted tracer concentration falls under 
the predicted value at the desired time. Thus, the starting tracer solution must be concentrated enough 
such that a concentration of 1 ppm can be measured by a highly sensitive technique. In this work, a tracer 
solution and a method of detection were selected. Preliminary results of chamber design will be shown 
and current challenges will be shared.  
 
 
 
 
 
